ARVO Annual Meeting
Apr 23 – Apr 27, 2023
APX3330 Oral Tablet in Diabetic Retinopathy
| Title: | ZETA-1 Phase 2 Trial to Determine the Safety and Efficacy of APX3330: a Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy |
| Presenter: | Daniel Su, M.D., Retina-Vitreous Associates Medical Group |
| Paper Session: | #205 Diabetic Retinopathy Medical |
| Wednesday, April 26, 2023, 10:45 AM – 11:00 AM CT | |
| Location: | La Nouvelle Ballroom AB |
| Abstract Number: | 3753 |
Nyxol Eye Drops in Dim Light Vision Disturbances and Presbyopia
| Title: | LYNX-1: A Phase 3 Randomized Placebo-Controlled Trial of Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbances |
| Presenter: Poster Session: |
Jay Pepose, M.D., Ph.D. #141 Presbyopia and Intraocular Lenses Tuesday, April 25, 2023, 8:45 AM – 10:30 AM CT |
| Location: | Exhibit Hall |
| Abstract number: | 2506 - B0008 |
| Title: | Phentolamine Ophthalmic Solution, with and without Low Dose Pilocarpine, Provides Durable Improvement in Distance Corrected Near Vision in Presbyopic Patients: A Responder Analysis |
| Presenter: | Mitchell Brigell, Ph.D. |
| Paper Session: | #297 Cataract and Intraocular Lenses Thursday, April 27, 2023, 1:45 PM – 2:00 PM CT |
| Location: | Room 255-257 |
| Abstract number: | 5423 |
Additional poster presentations at ARVO:
- VEGA-1 Phase 2 Trial: Phentolamine Ophthalmic Solution Maintains Pupillary Light Reflex with Improved Distance-Corrected Near Vision in Presbyopes (Ronil Patel, M.S.) Poster on Tuesday, April 25, 2023, 8:45 AM – 10:30 AM CT (Abstract number: 2507 - B0009)
- Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trial (Mina Sooch, M.B.A.) Poster on Tuesday, April 25, 2023, 11:45 AM – 1:30 PM CT (Abstract number: 3099 - C0231)